21:50 , Apr 20, 2017 |  BC Week In Review  |  Clinical News

ApoGraft: Ph I/II ApoGraft01 ongoing

An independent DSMB approved the enrollment of the next 2 patients in the first cohort of the open-label, Israeli Phase I/II ApoGraft01 trial evaluating transplanted ApoGraft exposed to FASL. The DSMB made the recommendation after...
21:56 , Feb 9, 2017 |  BC Week In Review  |  Clinical News

ApoGraft: Ph I/II started

Cellect began an open-label, Israeli Phase I/II trial to evaluate transplanted ApoGraft exposed to 10, 25, 50 or 100 ng/mL FASL in about 12 patients undergoing allogeneic stem cell transplantation (ASCT) from a matched related...
21:07 , Dec 2, 2016 |  BC Week In Review  |  Company News

Cellect, Hadassah deal

Hadassah's Hadasit Ltd. technology transfer arm partnered with Cellect to conduct preclinical studies of Cellect’s ApoGraft to treat graft-versus-host disease (GvHD). Hadassah will conduct the studies. ApoGraft consists of mobilized peripheral blood cells (MPBC) for...